News First drug backed for NHS use in untreated Hodgkin lymphoma Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated late-stage Hodgkin lymphoma.
News Pharma furious as UK Statutory Scheme rebate rate soars The UK pharma sector has reacted with consternation to the government's proposal to raise the Statutory Scheme rate to 32.2% in the last half of 2025.
R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Market Access Overcoming barriers for global CGT adoption Cell and gene therapies (CGT) have emerged as the next big thing in medicine, holding the power to deliver cures where none previously existed.
News Lyfegen partners EVERSANA on pricing, access resource Lyfegen and EVERSANA have joined forces to help pharma companies navigate an increasingly complex global drug pricing and access environment.
News Study finds big life expectancy deficit in adults with ADHD UK study finds adults with ADHD have a big shortfall in life expectancy, raising questions about diagnosis rates and treatment access.
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face